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The Effect of Propolis on Anthropometric Indices and Lipid Profile: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials
Running title: Propolis, anthropometric factors, and lipid profile.
Abstract
Background & objective(s): The current evidence base regarding the impact of propolis 
consumption on lipid profile in humans is equivocal. Thus, we sought to investigate the impact of 
propolis consumption on anthropometric indices and lipid profile in this meta-analysis. 
Methods: Cochrane Library, Scopus , PubMed, and Web of Science electronicdatabases were
searched up to December 2019. A random-effects model used to pool effect size. The leave-one­
out method used to conduct sensitivity analysis. 
Results: Five RCTs were included in this study. Our findings indicated a significant decrease in 
triglyceride (TG) (WMD: -3.91 mg/dl, 95% CI: -4.22, -3.60), and a significant increase in high-
density lipoprotein (HDL) (WMD: 3.41 mg/dl, 95% CI: 0.05, 6.76), however, for body mass index, 
weight, cholesterol (CL), and low-density lipoprotein (LDL), no significant alterations were
evident.
Conclusion: This study revealed that consumption of propolis is associated with a reduction in
TG levels, in addition to an increase in HDL levels. Nevertheless, additional research is required
to further delineate the relationship between propolis consumption and lipid profile.
Keywords: propolis; weight; body mass index; lipid profile
  
        
        
       
      
        
    
  
     
      
      
   
     
     
       
 
        
     
         
     
      
     
    
Introduction
Propolis is a naturally occurring, adhesive material, gathered by Apis mellifera L. (Honeybees),
from plant sources (1). It is used by honeybees to cement the honeycombs, in combination with
wax and salivary gland enzymes. In humans, propolis has been used in traditional medicine
because of its free radical scavenging properties and antimicrobial effects (2). Even in 
contemporary medicine, propolis remains a popular over-the-counter (OTC) medication, because
of its potential therapeutic applications in, among other illnesses, acne vulgaris, diabetic foot 
ulcers, and as a cough remedy (3).
Propolis is solid at room temperature; however, when it is heated, it becomes gelatinous with 
adhesive and flexible properties. It has a lipophilic nature and its color varies from yellow and 
green to dark brown, depending on the type of material used by the honeybees (4, 5). It is used
extensively in food and beverages for the prevention and improvement of some health conditions 
(6). Indeed, the continued use of propolis has garnered scientific interest in its chemical
composition and potential clinical applications (7). Approximately 300 constituents are found in
propolis, where the major components are flavonoids, aromatic aldehyde, alcohols, beta-steroids,
and terpenes. With regards to the flavonoids; flavanols, flavones, flavanones, dihydroflavonols,
and chalcones are the most abundant (8), and possess free radical scavenging potential, especially
in reactive nitrogen species, hydrogen peroxide, and reactive oxygen species (9, 10). Moreover, 
flavonoids can contribute to the inhibition of the Xanthine oxidase reaction, chelating the metal 
ions involved in the development of free radicals (11), thus, preventing peroxidation of lipids and
protecting the cell membrane. Propolis also comprises another powerful antioxidant, caffeic acid
phenyl ester, which prevents the formation of free radicals (12). Overall, propolis appears to 
prevent the peroxidation of lipids, regulates carbohydrate and lipoprotein metabolism, regulates
    
   
         
      
    
 
  
     
      
    
   
 
  
        
        
   
    
    
  
   
    
gene expression, suppresses the activity of cytokines, attenuates endothelial dysfunction, and
prevents aggregation of cytokines (13-16).
However, despite an increase in the number of studies evaluating the effect of propolis on weight,
body mass index, and lipid profile, to the best of the authors knowledge, no study has attempted 
to summarize the effect of propolis on the aforementioned parameters. Thus, we sought to
investigate the effect of propolis consumption on anthropometric indices and lipid profile.
Material and methods
The present study was conducted according PRISMA statement (17). Searches were conducted in 
Cochrane Library, Web of Science, PubMed, and Scopus, up to December 2019. Our search 
strategy in detailed in supplemental Table 1. The search was conducted by two of the authors. 
Disagreements in study selection were resolved through panel discussions method.
Eligibility Criteria
Clinical studies that investigated propolis supplementation and its’ resultant effect on weight, BMI,
cholesterol, triglyceride, LDL, and HDL were included in this study, if the following criteria were
met; followed a RCT study design, conducted an intervention using propolis, and, sufficient
baseline and post-intervention data were available. Furthermore, we adopted the following 
exclusion criteria, where non-interventional studies, studies with no placebo group, and studies 
that did not have sufficient data at baseline and post-intervention, were excluded.
Data extraction and Quality assessment
Two authors (J.R and A.S) evaluated the titles/abstracts, independently. Full-texts of the eligible
articles were examined to extract the required information. In any instance of disagreement, 
   
   
 
      
              
   




        
       
          
      
     
 
     
   
  
        
        
   
consensus was achieved through panel discussion with the author team. The Cochrane
Collaboration tool (18) was used to assess risk of bias. 
Statistical analysis
The SD change of the mean difference was calculated using the following formula: SD2 = [(SD 
baseline 2 + SD final 2) - (2 × R × SD baseline × SD final)]. In order to calculate the pooled effect
size, a random-effects model was employed. The I2 test was used to evaluate heterogeneity, whilst 
the Begg’s and Egger’s tests were used to assess publication bias. STATA 11 software (StataCorp, 
College Station, Texas, USA) used to conduct all statistical analyses.
Results: 
As depicted in Figure 1, following the primary systematic search, and removal of duplicated
studies, 915 papers were identified for title and abstract screening. Accordingly, 899 papers were
excluded due to irrelevant title and abstracts, resulting in 16 papers included for full text
evaluation. Of the 16 studies, 10 studies did not meet our inclusion criteria, so they were excluded; 
subsequently, five papers were included in the present study (19-23).
Study characteristics
The characteristics of the included studies are detailed in Table 1, where all were conducted on 
both genders and published between 2017-2019. The included studies were conducted in Iran (19, 
20, 22), Chile (21), and Japan (23), respectively, and utilized a mean propolis dose of 906 mg per 
day, with a mean age of 53.77y. Four studies were conducted on diabetic patients, and one on ‘at 
risk’ adults. The mean intervention duration was 10 weeks, whilst the quality of included studies
was good (Figure 2).
 
      
     
     
        
   
        
      
        
       
         
 
  
    
   
               
     
 
      
   
     
Meta-analysis results
Four studies, including 278 participants, reported weight and BMI as anthropometric outcome
measures. According to Figure 3, combined results of these four studies did not show any
significant change in the propolis group, vs. control group, in weight (WMD: -0.69 kg, 95% CI: ­
1.98, 0.60, I2 = 0%) and BMI (WMD: -0.22 kg/m2, 95% CI: -0.66, 0.22, I2 = 0%) (19-22). There
was no significant heterogeneity evident in the pooled results of weight and BMI. 
Four studies, with a total of 298 participants, reported lipid profile as an outcome measure (CL,
TG, HDL, and LDL) (19-21, 23). Pooled results of these studies show no significant change in CL
(WMD: 4.69 mg/dl, 95% CI: -1.09, 22.48, I2 = 94%) and LDL (WMD: -0.24 mg/dl, 95% CI: ­
5.72, 5.23, I2 = 55%) levels, however, TG (WMD: -3.91 mg/dl, 95% CI: -4.22, -3.60, I2 = 0%) and 
HDL (WMD: 3.41 mg/dl, 95% CI: 0.05, 6.76, I2 = 99%) were significantly lower and higher, 
respectively, compared to the control group. 
Risk of bias
A funnel plot of included studies did not show any asymmetry between included studies
(Supplemental Figure 1). Furthermore, the Begg’s and Egger’s tests were non-significant for
weight (p = 0.17, p = 0.33), BMI (p = 0.68, p = 0.62), CL (p = 0.49, p = 0.45), TG (p = 0.49, p =
0.85), HDL (p = 0.99, p = 0.48), and LDL (p = 0.34, p = 0.44), respectively.
Discussion
In the present study, we pooled results from five trials concerning the effect of propolis 
consumption on anthropometric indices and lipid profile. According to results consumption of 
propolis did not yield any significant effect on weight, BMI, CL, and LDL. However, the pooled 
        
  
    
     
    
    
   
      
 
      
     
      
   
      
     
  
   
   
     
    
    
  
  
estimates demonstrated that consumption of propolis was associated with a significant decrease in
TG levels, whilst HDL levels were significantly increased.
Propolis, colloquially known as bee glue, has long been reported to have various beneficial health 
effects. Indeed, these effects are attributed to anti-inflammatory (24), antioxidant (25), anti­
microbial (26), and immunomodulatory properties (27). Propolis is known to possess over 300
different compounds, and the main biologically active ingredients are flavonoids, polyphenols, 
vitamins, amino acids, and caffeic acid phenethyl ester, respectively (28). These compounds
combat oxidative stress by eliminating the release of reactive oxygen species, such as free radicals,
hydrogen peroxide, and nitric oxide (29).
In vivo and in vitro studies have demonstrated the potential cardioprotective properties of propolis 
via inhibition of LDL peroxidation (30), limitation of inflammatory cytokines (31), regulation of 
glucose metabolism (32), prevention of atherosclerotic plaque formation (33), as well as 
improvement of endothelial function and decreases in aggravation of thrombocytes (34). These
effects can be particularly beneficial for patients with existing metabolic abnormalities, such as 
those with type 2 diabetes mellitus. However, despite a large number of experimental data, there
is a lack of human studies to have evaluated the clinical efficacy of propolis. 
In this study, individuals receiving propolis showed statistically significant reductions in the levels
of TG, in addition to increased levels of HDL, compared to the control group. These outcomes
may be promising in the management of individuals with altered lipid profile, conceivably
representing an alternative to many pharmaceutical options. In particular, Hesadi et al and Samadi 
et al, respectively, reported significantly lower LDL levels by the end of the trial (21). Samadi and 
colleagues also demonstrated additional benefits through reductions in total cholesterol levels, 
while, Zakerkish et al showed propolis could elicit an increased concentration of HDL (20).
     
   
     
      
   
   
     
      
 
      
    
      
        
      
     
   
      
  
      
  
       
     
     
A putative mechanism for the beneficial effect of propolis on lipid profile may be that ATP-binding 
cassette transporters, which are associated with HDL formation and peripheral tissue efflux, are
expressed to a greater extent in the liver proteins following supplementation (20). Furthermore,
Mujica et al., demonstrated, in a RCT, that 90 days consumption of propolis significantly increased
HDL-C levels (22), and Zakerkish et al. demonstrated that, in T2DM patients, supplementation
with Iranian propolis yielded increases in HDL-C. Indeed, it is accepted that HDL-C represents an 
significant lipoparticle which is capable of providing protection against various cardiovascular
diseases, prevention of LDL oxidation, and neutralization of atherogenic effects within the arterial
walls (20).
This study represents the first meta-analysis to have examined the influence of propolis 
consumption on anthropometric indices and lipid profile. Accordingly, there are some strengths
and limitations that must be recognized. One of the biggest strengths of this study is the 
methodological approach, where the results from five RCTs were shown to be consistent, as
demonstrated by Funnel plots. Moreover, four out of five included studies were double-blinded, 
two of which were placebo-controlled. Finally, the bias assessment conducted in our study
demonstrated minimal bias, allowing us to assert veracity in our results. Notwithstanding the 
strengths highlighted above; there are several limitations that should be addressed. First, studies 
evaluated different types of propolis. Indeed, it is not certain to what extent they differ in biological 
activity and whether there could be any clinical implication to their interchangeable use. Second, 
discrepancies existed in the doses used per day; however, to date, there is no standard dosage
currently advocated, and thus, future investigations should delineate the effects of various doses 
of propolis. Third, despite the robust methodology of the trials analyzed, the study population was
small; it is therefore difficult to correctly estimate the exact impact of propolis in a wider 
  
   
 
         
  
       
 
 
       
     
  
 
    
      





population. Fourth, the intervention period in all studies was limited to 3 months, which might not
be sufficient to draw definite conclusions regarding the sustainability and long-term effects of 
propolis. 
Future studies are encouraged to recruit large sample sizes, using crossover study designs, to yield
more robust evidence. In addition, investigations should focus on the long-term evaluation, dosage
comparison, as well as considering the type of propolis, to provide greater insights into the clinical 
efficacy of propolis. 
Conclusion
In conclusion, our results show that, following propolis consumption, TG levels were significantly
decreased, whilst HDL levels were significantly increased. However, further research is required
to better elucidate the relationship between propolis consumption and lipid profile markers.
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